7-year results from MUST

November 11, 2017

The MUST trial compared the effectiveness of systemic therapy vs. fluocinolone acetonide implant for severe uveitis. Intermediate, posterior and panuveitis patients were included. In a nonprespecified 7-year observational follow-up of 215 participants from the randomized clinical trial, patients who had systemic therapy had significantly better visual acuity compared with those who received the fluocinolone acetonide implant, by a mean of 7 letters. Previously, the trial had shown no difference at 2 years. Findings are limited by a 30% loss to follow up, with possible selection bias.